CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), failed to prevent motor neurons loss and lung function decline relative to a placebo, according to top-line data from the RESCUE-ALS Phase 2 clinical trial. The trial, in other words, did not meet its primary…
Measurements taken of muscle using ultrasound could be useful in diagnosing or managing amyotrophic lateral sclerosis (ALS), a small study suggests. The study, “Application of Muscle Ultrasound for the evaluation of Patients with Amyotrophic Lateral Sclerosis: An observational Cross‐Sectional Study,” was published in Muscle & Nerve.
Combining structural brain imaging with molecular and clinical biomarkers allows for a detailed assessment of a patient’s clinical state, regardless of age and amyotrophic lateral sclerosis progression, a new study suggests. The study, “Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of…
